CSPC Innovation Pharmaceutical Future Growth
Future criteria checks 5/6
CSPC Innovation Pharmaceutical is forecast to grow earnings and revenue by 23.9% and 29.9% per annum respectively. EPS is expected to grow by 20.1% per annum. Return on equity is forecast to be 14.4% in 3 years.
Key information
23.9%
Earnings growth rate
20.1%
EPS growth rate
| Pharmaceuticals earnings growth | 18.9% |
| Revenue growth rate | 29.9% |
| Future return on equity | 14.4% |
| Analyst coverage | Low |
| Last updated | 16 May 2024 |
Recent future growth updates
Recent updates
CSPC Innovation Pharmaceutical's (SZSE:300765) Weak Earnings May Only Reveal A Part Of The Whole Picture
Apr 29
CSPC Innovation Pharmaceutical (SZSE:300765) Will Pay A Larger Dividend Than Last Year At CN¥0.32
Apr 25CSPC Innovation Pharmaceutical Co., Ltd.'s (SZSE:300765) P/E Still Appears To Be Reasonable
Apr 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,443 | 1,246 | 1,548 | 1,303 | 4 |
| 12/31/2025 | 4,090 | 952 | 930 | 918 | 5 |
| 12/31/2024 | 3,064 | 722 | 240 | 549 | 5 |
| 3/31/2024 | 2,307 | 705 | -404 | -344 | N/A |
| 12/31/2023 | 2,502 | 756 | 832 | 927 | N/A |
| 9/30/2023 | 2,670 | 740 | 864 | 997 | N/A |
| 6/30/2023 | 2,729 | 742 | 715 | 866 | N/A |
| 3/31/2023 | 2,804 | 732 | 667 | 831 | N/A |
| 1/1/2023 | 2,626 | 726 | 527 | 641 | N/A |
| 9/30/2022 | 2,694 | 666 | 294 | 582 | N/A |
| 6/30/2022 | 2,384 | 562 | 225 | 461 | N/A |
| 3/31/2022 | 2,034 | 433 | 113 | 350 | N/A |
| 1/1/2022 | 1,850 | 393 | 97 | 292 | N/A |
| 9/30/2021 | 1,333 | 287 | 167 | 250 | N/A |
| 6/30/2021 | 1,338 | 284 | 188 | 277 | N/A |
| 3/31/2021 | 1,319 | 311 | 201 | 302 | N/A |
| 12/31/2020 | 1,317 | 300 | 231 | 349 | N/A |
| 9/30/2020 | 1,329 | 317 | 246 | 396 | N/A |
| 6/30/2020 | 1,290 | 316 | 199 | 344 | N/A |
| 3/31/2020 | 1,270 | 290 | 228 | 357 | N/A |
| 12/31/2019 | 1,257 | 273 | 209 | 315 | N/A |
| 9/30/2019 | 1,299 | 266 | 163 | 223 | N/A |
| 6/30/2019 | 1,277 | 251 | 159 | 233 | N/A |
| 3/31/2019 | 1,281 | 230 | 140 | 191 | N/A |
| 12/31/2018 | 1,240 | 224 | 101 | 160 | N/A |
| 9/30/2018 | 1,149 | 214 | 68 | 119 | N/A |
| 6/30/2018 | 1,111 | 198 | 12 | 49 | N/A |
| 3/31/2018 | 1,064 | 191 | -33 | 18 | N/A |
| 12/31/2017 | 1,031 | 195 | N/A | 1 | N/A |
| 12/31/2016 | 890 | 207 | N/A | 137 | N/A |
| 12/31/2015 | 742 | 116 | N/A | 112 | N/A |
| 12/31/2014 | 651 | 108 | N/A | 93 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300765's forecast earnings growth (23.9% per year) is above the savings rate (2.9%).
Earnings vs Market: 300765's earnings (23.9% per year) are forecast to grow faster than the CN market (23.3% per year).
High Growth Earnings: 300765's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300765's revenue (29.9% per year) is forecast to grow faster than the CN market (14.1% per year).
High Growth Revenue: 300765's revenue (29.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300765's Return on Equity is forecast to be low in 3 years time (14.4%).